Dr. Pat Soon-Shiong ✓

@DrPatrick · Los Angeles · joined 03 Sep 2009

Chairman of Chan Soon-Shiong Family Foundation, Exec Chairman ImmunityBio, Chairman and Chief Executive Officer of Los Angeles Times Media Group (LATMG)

155 737Followers

1 574Following

2 292Posts total

379.4KViews on collected posts

Against accounts of the same size

10 posts from the last 90 days, next to the 100K–1M follower range. shown to more people than peers of the same size.

Median views48 939this account5 854median for 100K–1M

Reach, %31.42%this account2.44%median for 100K–1M

Engagement, %1.75%this account1.42%median for 100K–1M

Metric	This account	Median for 100K–1M	Ratio
Median views per post	48 939	5 854	8.36×
Reach (views ÷ followers)	31.42%	2.44%	12.9×
Engagement rate	1.75%	1.42%	1.23×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

58.4K15 Aug

53.1K17 Aug

22.3K23 Aug

78.7K24 Aug

434

722

783

45.1K26 Aug

67K

52.8K27 Aug

Last 10 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.46%15 Aug

1.57%17 Aug

2.91%23 Aug

1.65%24 Aug

1.84%

3.32%

1.53%

0.95%26 Aug

2.34%

1.86%27 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 1.42%.

What the audience does

Likes77.1%5 077 in total

Reposts10.2%672 in total

Replies4.1%268 in total

Quotes0.8%50 in total

Bookmarks7.9%518 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

Pleased to see the fruits of our ongoing clinical trials in patients with colon cancer and the goal to reduce the risk of the cancer coming back. The goal to prevent colon cancer is even more challenging - a cancer vaccine. Our NCI sponsored trial has taken on this challenge - a 52.8K views · 828 likes · 107 reposts · 34 replies 27 Aug 2026 Proud moment for our team and for patients across Europe. Our first EU (German) labeling and packaging run for ANKTIVA is complete. These vials represent more than manufacturing. They mark the next step in bringing this IL-15 immunotherapy to patients with BCG-unresponsive ht 67K views · 1.3K likes · 163 reposts · 75 replies 26 Aug 2026 Last round of treatment yesterday at ImmunityBio. ❤️ I’ve been incredibly fortunate to participate in a single-patient investigational new drug (IND) protocol with the goal of reducing my risk of colon cancer recurrence after my extended right hemicolectomy surgery last year. ht 45.1K views · 352 likes · 38 reposts · 33 replies 26 Aug 2026 @DrPatrick What happened to your Leonardo cell manufacturing? It's been a couple months since any update. 783 views · 12 likes · 0 reposts · 0 replies 24 Aug 2026 @DrPatrick I'd really like to be involved in an anktiva trial. Stage IV esophagus cancer. I would love to have a 2nd chance at life. 722 views · 21 likes · 0 reposts · 3 replies 24 Aug 2026 @DrPatrick Anktiva since ALC matters 434 views · 8 likes · 0 reposts · 0 replies 24 Aug 2026 I see the amazing revolution of PRECISION tumor-targeted radio therapy with these cancer fighting isotopes manufactured by Shine. This will replace tissue damaging current radiation therapy . The field of antibody and peptide radio-isotope oncology is about to explode …but 78.7K views · 1.1K likes · 151 reposts · 47 replies 24 Aug 2026 Destroying jobs through ignorance. Those who can do, those who can’t teach …so true when you have never had the responsibility to make a payroll ⁦@latimes⁩ https://t.co/DqPmbI0c6P 22.3K views · 548 likes · 66 reposts · 36 replies 23 Aug 2026 Thank you for sharing this important difference between IL-2 and IL-15. This error of insight had led to the development for decades of the wrong cytokine ..one stimulates suppressor cells while the other killer cells. ! Important paper to read and understand. 53.1K views · 695 likes · 105 reposts · 29 replies 17 Aug 2026 All the real #cancer #immunotherapy experts know that IL-15 #anktiva by $IBRX is the biggest breakthrough in this field. https://t.co/sb7f53Gd5g 58.4K views · 213 likes · 42 reposts · 11 replies 15 Aug 2026